iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
26 févr. 2024 07h45 HE
|
iBio, Inc.
– Deal includes $1 million upfront and potential future milestone payments – – iBio’s proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – ...
iBio Announces Participation in 23rd Annual PepTalk Conference
16 janv. 2024 08h15 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that...
iBio Amends and Extends Maturity of Credit Agreement
26 déc. 2023 07h15 HE
|
iBio, Inc.
– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) --...
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
05 déc. 2023 08h00 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of...
iBio Announces Reverse Stock Split
27 nov. 2023 17h20 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of...
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
01 nov. 2023 08h24 HE
|
iBio, Inc.
- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action - BRYAN, Texas and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- iBio,...
iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
10 oct. 2023 08h00 HE
|
iBio, Inc.
- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries - BRYAN, Texas...
iBio Explains Recent Filing of Registration Statement
02 oct. 2023 06h45 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- In response to investor inquiries received about the post-effective amendment to its Form S-3 on Form S-1 (the “Post-Effective...
iBio Announces Filing of 2023 Annual Report on SEC Form 10-K
27 sept. 2023 16h19 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the...
iBio Announces Amendment to Credit Agreement with Woodforest
21 sept. 2023 16h05 HE
|
iBio, Inc.
– Extends maturity date to December 31, 2023 –– Allows time to close pending sale of CDMO facility –BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or...